Updates From COMMANDS at ASH 2024
Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk myelodysplastic syndromes (LR-MDS), demonstrated the long-term clinical value of luspatercept in improving hemoglobin levels and reducing transfusion dependence, with updated efficacy results presented by Garcia-Manero et al at ASH 2024.
Video content above is prompted by the following:
- Discuss the long-term clinical value from the COMMANDS study of luspatercept vs epoetin alfa in patients with ESA-naive, transfusion-dependent LR-MDS.
- First, briefly introduce COMMANDS: study design and key efficacy results
- Then, discuss the long-term responses
Recent Videos
Related Content
